Here's how NATURE.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NATURE . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Nature.com Make Money
  6. How Much Does Nature.com Make
  7. Keywords
  8. Topics
  9. Questions
  10. Schema
  11. Social Networks
  12. External Links
  13. Analytics And Tracking
  14. Libraries
  15. Hosting Providers
  16. CDN Services

We are analyzing https://www.nature.com/articles/s41587-021-01038-8.

Title:
Identification of tumor antigens with immunopeptidomics | Nature Biotechnology
Description:
The identification of actionable tumor antigens is indispensable for the development of several cancer immunotherapies, including T cell receptor–transduced T cells and patient-specific mRNA or peptide vaccines. Most known tumor antigens have been identified through extensive molecular characterization and are considered canonical if they derive from protein-coding regions of the genome. By eluting human leukocyte antigen-bound peptides from tumors and subjecting these to mass spectrometry analysis, the peptides can be identified by matching the resulting spectra against reference databases. Recently, mass-spectrometry-based immunopeptidomics has enabled the discovery of noncanonical antigens—antigens derived from sequences outside protein-coding regions or generated by noncanonical antigen-processing mechanisms. Coupled with transcriptomics and ribosome profiling, this method enables the identification of thousands of noncanonical peptides, of which a substantial fraction may be detected exclusively in tumors. Spectral matching against the immense noncanonical reference may generate false positives. However, sensitive mass spectrometry, analytical validation and advanced bioinformatics solutions are expected to uncover the full landscape of presented antigens and clinically relevant targets. Chong et al. review how the integration of mass spectrometry with proteogenomic approaches can identify noncanonical antigens.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

  • Education
  • Science
  • Health & Fitness

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌆 Monumental Traffic: 20M - 50M visitors per month


Based on our best estimate, this website will receive around 42,554,915 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}


Display Ads {🎯}

$536,300 per month
Our estimates place Nature.com's monthly online earnings from display ads at $357,503 to $983,134.

Keywords {🔍}

pubmed, article, google, scholar, cas, central, cancer, nature, cell, nat, peptide, human, antigens, mass, peptides, immunol, res, cells, antigen, mol, identification, spectrometry, analysis, tumor, access, sci, proteom, proteomics, noncanonical, open, melanoma, class, data, immunopeptidomics, bassanisternberg, immunotherapy, rev, mhc, hla, presentation, splicing, endogenous, content, search, genome, profiling, commun, translation, methods, spliced,

Topics {✒️}

nature portfolio journals ny-eso-1–reactive t-cell receptor permissions reprints privacy policy nature portfolio advanced bioinformatics solutions george coukos & michal bassani-sternberg ny-eso-1–specific tcr–engineered cancer research advertising author information authors social media mass-spectrometry-based immunopeptidomics mass spectrometry-based identification multi-omic data analysis target-decoy search strategy mass spectrometry-based proteomics alternative tumour-specific antigens proteasome-catalyzed peptide cis-splicing author correspondence michal bassani-sternberg noncanonical antigen-processing mechanisms mhc-bound peptide epitopes peptide-signal amplification strategy shared tumor-specific antigens targetable tumor-specific antigens large-scale protein identifications mono-allelic cells enables cell-based cancer immunotherapy canonical reading frames data-independent acquisition proteomics neoepitope-driven tumor rejection cd8+ t-cell immunity annotated protein-coding genes trans-spliced peptide ligands trans-spliced peptide ligands ribosome profiling data making t-cell products nature+ nature 543 nature 427 nature 451 nature 547 nature 564 nature 565 nature post-translationally spliced peptides de novo sequencing post-translational modification analysis noncanonical antigens—antigens derived

Questions {❓}

  • Adding a new separation dimension to MS and LC–MS: what is the utility of ion mobility spectrometry?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Identification of tumor antigens with immunopeptidomics
         description:The identification of actionable tumor antigens is indispensable for the development of several cancer immunotherapies, including T cell receptor–transduced T cells and patient-specific mRNA or peptide vaccines. Most known tumor antigens have been identified through extensive molecular characterization and are considered canonical if they derive from protein-coding regions of the genome. By eluting human leukocyte antigen-bound peptides from tumors and subjecting these to mass spectrometry analysis, the peptides can be identified by matching the resulting spectra against reference databases. Recently, mass-spectrometry-based immunopeptidomics has enabled the discovery of noncanonical antigens—antigens derived from sequences outside protein-coding regions or generated by noncanonical antigen-processing mechanisms. Coupled with transcriptomics and ribosome profiling, this method enables the identification of thousands of noncanonical peptides, of which a substantial fraction may be detected exclusively in tumors. Spectral matching against the immense noncanonical reference may generate false positives. However, sensitive mass spectrometry, analytical validation and advanced bioinformatics solutions are expected to uncover the full landscape of presented antigens and clinically relevant targets. Chong et al. review how the integration of mass spectrometry with proteogenomic approaches can identify noncanonical antigens.
         datePublished:2021-10-11T00:00:00Z
         dateModified:2021-10-11T00:00:00Z
         pageStart:175
         pageEnd:188
         sameAs:https://doi.org/10.1038/s41587-021-01038-8
         keywords:
            Bioinformatics
            MHC
            Tumour immunology
            Life Sciences
            general
            Biotechnology
            Biomedicine
            Agriculture
            Biomedical Engineering/Biotechnology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41587-021-01038-8/MediaObjects/41587_2021_1038_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41587-021-01038-8/MediaObjects/41587_2021_1038_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41587-021-01038-8/MediaObjects/41587_2021_1038_Fig3_HTML.png
         isPartOf:
            name:Nature Biotechnology
            issn:
               1546-1696
               1087-0156
            volumeNumber:40
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Chloe Chong
               affiliation:
                     name:University of Lausanne
                     address:
                        name:Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland
                        type:PostalAddress
                     type:Organization
                     name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV)
                     address:
                        name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:George Coukos
               url:http://orcid.org/0000-0001-8813-7367
               affiliation:
                     name:University of Lausanne
                     address:
                        name:Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland
                        type:PostalAddress
                     type:Organization
                     name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV)
                     address:
                        name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michal Bassani-Sternberg
               url:http://orcid.org/0000-0002-1934-954X
               affiliation:
                     name:University of Lausanne
                     address:
                        name:Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland
                        type:PostalAddress
                     type:Organization
                     name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV)
                     address:
                        name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Identification of tumor antigens with immunopeptidomics
      description:The identification of actionable tumor antigens is indispensable for the development of several cancer immunotherapies, including T cell receptor–transduced T cells and patient-specific mRNA or peptide vaccines. Most known tumor antigens have been identified through extensive molecular characterization and are considered canonical if they derive from protein-coding regions of the genome. By eluting human leukocyte antigen-bound peptides from tumors and subjecting these to mass spectrometry analysis, the peptides can be identified by matching the resulting spectra against reference databases. Recently, mass-spectrometry-based immunopeptidomics has enabled the discovery of noncanonical antigens—antigens derived from sequences outside protein-coding regions or generated by noncanonical antigen-processing mechanisms. Coupled with transcriptomics and ribosome profiling, this method enables the identification of thousands of noncanonical peptides, of which a substantial fraction may be detected exclusively in tumors. Spectral matching against the immense noncanonical reference may generate false positives. However, sensitive mass spectrometry, analytical validation and advanced bioinformatics solutions are expected to uncover the full landscape of presented antigens and clinically relevant targets. Chong et al. review how the integration of mass spectrometry with proteogenomic approaches can identify noncanonical antigens.
      datePublished:2021-10-11T00:00:00Z
      dateModified:2021-10-11T00:00:00Z
      pageStart:175
      pageEnd:188
      sameAs:https://doi.org/10.1038/s41587-021-01038-8
      keywords:
         Bioinformatics
         MHC
         Tumour immunology
         Life Sciences
         general
         Biotechnology
         Biomedicine
         Agriculture
         Biomedical Engineering/Biotechnology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41587-021-01038-8/MediaObjects/41587_2021_1038_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41587-021-01038-8/MediaObjects/41587_2021_1038_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41587-021-01038-8/MediaObjects/41587_2021_1038_Fig3_HTML.png
      isPartOf:
         name:Nature Biotechnology
         issn:
            1546-1696
            1087-0156
         volumeNumber:40
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Chloe Chong
            affiliation:
                  name:University of Lausanne
                  address:
                     name:Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland
                     type:PostalAddress
                  type:Organization
                  name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV)
                  address:
                     name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:George Coukos
            url:http://orcid.org/0000-0001-8813-7367
            affiliation:
                  name:University of Lausanne
                  address:
                     name:Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland
                     type:PostalAddress
                  type:Organization
                  name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV)
                  address:
                     name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michal Bassani-Sternberg
            url:http://orcid.org/0000-0002-1934-954X
            affiliation:
                  name:University of Lausanne
                  address:
                     name:Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland
                     type:PostalAddress
                  type:Organization
                  name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV)
                  address:
                     name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature Biotechnology
      issn:
         1546-1696
         1087-0156
      volumeNumber:40
Organization:
      name:Nature Publishing Group US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Lausanne
      address:
         name:Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland
         type:PostalAddress
      name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV)
      address:
         name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
         type:PostalAddress
      name:University of Lausanne
      address:
         name:Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland
         type:PostalAddress
      name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV)
      address:
         name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
         type:PostalAddress
      name:University of Lausanne
      address:
         name:Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland
         type:PostalAddress
      name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV)
      address:
         name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Chloe Chong
      affiliation:
            name:University of Lausanne
            address:
               name:Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland
               type:PostalAddress
            type:Organization
            name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV)
            address:
               name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
               type:PostalAddress
            type:Organization
      name:George Coukos
      url:http://orcid.org/0000-0001-8813-7367
      affiliation:
            name:University of Lausanne
            address:
               name:Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland
               type:PostalAddress
            type:Organization
            name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV)
            address:
               name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
               type:PostalAddress
            type:Organization
      name:Michal Bassani-Sternberg
      url:http://orcid.org/0000-0002-1934-954X
      affiliation:
            name:University of Lausanne
            address:
               name:Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland
               type:PostalAddress
            type:Organization
            name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV)
            address:
               name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland
      name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
      name:Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland
      name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
      name:Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland
      name:Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(421)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mxa-002c5801.gslb.pphosted.com
  • mxb-002c5801.gslb.pphosted.com

Name Servers:

  • pdns1.ultradns.net
  • pdns2.ultradns.net
  • pdns3.ultradns.org
  • pdns4.ultradns.org
  • pdns5.ultradns.info
  • pdns6.ultradns.co.uk

CDN Services {📦}

  • Crossref

4.64s.